An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
Approximately 50% of patients with neuroendocrine cancers present with metastasis, a vast
majority to the liver. In such patients, one treatment option for liver-directed therapy is
surgical resection. However, a significant proportion of patients are not eligible for
resection because of patient factors (age, comorbidities) or tumor-related factors.
There have been scant data on the utility of EBRT (external-beam radiotherapy) and SABR
(stereotactic ablative radiotherapy) for metastatic neuroendocrine tumors of the liver. This
study will measure the effects of concurrent everolimus with external-beam radiotherapy to
the liver for metastatic neuroendocrine New methods of tumor assessment are needed in NETs.
Three new techniques are being developed at the Sunnybrook Research Institute to assess
tumour response to treatment: (1) contrast enhanced ultrasound; (2) perfusion CT; and (3)
perfusion MRI. These methods are devised to measure tumour perfusion and blood flow as
response indicators and can measure cell death non-invasively.
1. Concurrent everolimus given with external-beam radiotherapy to the liver for metastatic
neuroendocrine tumors of the liver will enhance the efficacy of radiotherapy and add
little, if any, toxicity
2. New radiological measures of CEUS and DCE-CT are effective measure to delineate tumor
response in NETs.